Literature DB >> 24131309

Polypharmacy and drug omissions across hospices in Northern Ireland.

Emma Lundy1, Damien McMullan, Patrick McShane, Matthew Williams, Max Watson, Clare White.   

Abstract

BACKGROUND: Polypharmacy and drug omissions (DO) (i.e., drugs prescribed but not administered) may impact on quality of life of hospice inpatients. AIM: The study's objective was to assess for polypharmacy and DO across hospice inpatient units in Northern Ireland (NI).
DESIGN: A retrospective chart review of consecutive admissions to five adult hospices in NI in 2011-2012 was performed. Only regularly prescribed oral and nebulized medications were analyzed.
RESULTS: Inpatient admissions (n=138) were reviewed (58% male, median age 68, 91% had cancer). The average number of regularly prescribed medications was eight (range 0-17) on admission, 10 (1-21) at discharge, and two (0-15) at time of death. Of all prescribed doses, 8.8% were omitted. The most frequent DOs were laxatives (38%), mouth care (11%), and mineral supplements (9%). Reasons for DO included patient refusal (46%), patient asleep or drowsy (20%), and drug not available (7%). DOs numbering 197 lasted 24 to 72 hours. No action was taken by medical staff for 79% of these. DOs numbering 85 lasted over 72 hours. While fewer drug doses were prescribed for patients who died during admission, the proportion of DO was higher (12.4%) than for those discharged (6.9%). DO increased in the last week of life (23%).
CONCLUSIONS: Polypharmacy is prevalent among hospice inpatients. Drugs omitted amounted to 8.8%, with the frequency of DO increasing in those who were dying. Documentation justifying DO was lacking. Daily focused drug chart review, pharmacy support, and electronic prescribing may all help to reduce and rationalize medication burden and aid prompt and effective management of DO.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131309     DOI: 10.1089/jpm.2013.0090

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  8 in total

1.  Deprescribing in palliative care.

Authors:  Jo Thompson
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

2.  Changes in medication profile among patients with advanced cancer admitted to an acute palliative care unit.

Authors:  David Hui; Zhijun Li; Gary B Chisholm; Neha Didwaniya; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2014-08-16       Impact factor: 3.603

3.  A study on prevalence and associations of non-robustness in older adults aged 65 years and above attending a general practitioner clinic in Ang Mo Kio.

Authors:  Junjie Aw; Eng Sing Lee; Grace Chiang; Boon Yeow Tan
Journal:  Singapore Med J       Date:  2021-06       Impact factor: 1.858

Review 4.  Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review.

Authors:  Cathal A Cadogan; Melanie Murphy; Miriam Boland; Kathleen Bennett; Sarah McLean; Carmel Hughes
Journal:  Explor Res Clin Soc Pharm       Date:  2021-07-23

Review 5.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

6.  Prevalence, nature and risk factors for medication administration omissions in English NHS hospital inpatients: a retrospective multicentre study using Medication Safety Thermometer data.

Authors:  Paryaneh Rostami; Calvin Heal; Abigail Harrison; Gareth Parry; Darren M Ashcroft; Mary P Tully
Journal:  BMJ Open       Date:  2019-06-09       Impact factor: 2.692

7.  Polypharmacy in the terminal stage of cancer.

Authors:  Katharina A Kierner; Dietmar Weixler; Eva K Masel; Verena Gartner; Herbert H Watzke
Journal:  Support Care Cancer       Date:  2015-11-05       Impact factor: 3.359

8.  Medication omission rates in New Zealand residential aged care homes: a national description.

Authors:  Stephanie M Garratt; Ngaire M Kerse; Kathryn Peri; Monique F Jonas
Journal:  BMC Geriatr       Date:  2020-08-05       Impact factor: 3.921

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.